| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 293 | 2024 | 3763 | 17.270 |
Why?
|
| Antirheumatic Agents | 168 | 2024 | 1374 | 17.250 |
Why?
|
| Methotrexate | 100 | 2023 | 1719 | 9.080 |
Why?
|
| Oxazines | 9 | 2018 | 341 | 2.360 |
Why?
|
| Receptors, Tumor Necrosis Factor | 22 | 2015 | 585 | 2.290 |
Why?
|
| Rheumatoid Factor | 12 | 2024 | 185 | 2.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 36 | 2018 | 4357 | 1.860 |
Why?
|
| Antibodies, Monoclonal | 39 | 2018 | 9185 | 1.760 |
Why?
|
| Biological Products | 13 | 2024 | 916 | 1.580 |
Why?
|
| Double-Blind Method | 53 | 2024 | 12427 | 1.480 |
Why?
|
| Rheumatic Diseases | 18 | 2022 | 639 | 1.410 |
Why?
|
| Severity of Illness Index | 77 | 2024 | 15840 | 1.390 |
Why?
|
| Drug Therapy, Combination | 46 | 2023 | 6498 | 1.340 |
Why?
|
| Immunoglobulin G | 24 | 2015 | 4541 | 1.260 |
Why?
|
| Pyridines | 10 | 2018 | 2879 | 1.230 |
Why?
|
| Immunoconjugates | 10 | 2013 | 949 | 1.120 |
Why?
|
| Rheumatology | 16 | 2021 | 611 | 1.110 |
Why?
|
| Arthritis | 8 | 2024 | 666 | 1.030 |
Why?
|
| Treatment Outcome | 100 | 2024 | 65017 | 0.990 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2014 | 2418 | 0.930 |
Why?
|
| Lung Diseases, Interstitial | 9 | 2024 | 911 | 0.890 |
Why?
|
| Gout | 5 | 2022 | 620 | 0.870 |
Why?
|
| Arthritis, Gouty | 1 | 2022 | 28 | 0.840 |
Why?
|
| Polyethylene Glycols | 7 | 2022 | 1189 | 0.830 |
Why?
|
| Azetidines | 3 | 2019 | 141 | 0.820 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2014 | 2873 | 0.820 |
Why?
|
| Middle Aged | 199 | 2024 | 220352 | 0.810 |
Why?
|
| Registries | 23 | 2023 | 8469 | 0.780 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2012 | 465 | 0.780 |
Why?
|
| Polyglutamic Acid | 2 | 2019 | 44 | 0.770 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2021 | 22 | 0.770 |
Why?
|
| Humans | 396 | 2024 | 760621 | 0.730 |
Why?
|
| Hand Joints | 3 | 2023 | 58 | 0.730 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2018 | 114 | 0.720 |
Why?
|
| Abortion, Criminal | 1 | 2019 | 2 | 0.710 |
Why?
|
| C-Reactive Protein | 19 | 2024 | 3839 | 0.700 |
Why?
|
| Drug Substitution | 2 | 2024 | 296 | 0.690 |
Why?
|
| Female | 240 | 2024 | 391270 | 0.650 |
Why?
|
| Aged | 151 | 2024 | 169152 | 0.640 |
Why?
|
| Adult | 144 | 2024 | 219994 | 0.640 |
Why?
|
| Male | 215 | 2024 | 359744 | 0.630 |
Why?
|
| Immunosuppressive Agents | 13 | 2020 | 4166 | 0.580 |
Why?
|
| Remission Induction | 19 | 2021 | 2392 | 0.580 |
Why?
|
| Morpholines | 9 | 2018 | 583 | 0.580 |
Why?
|
| Arthritis, Psoriatic | 9 | 2019 | 219 | 0.560 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2017 | 60 | 0.560 |
Why?
|
| Aminopyridines | 9 | 2018 | 564 | 0.550 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 388 | 0.530 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 11 | 2020 | 2282 | 0.520 |
Why?
|
| Anaphylaxis | 1 | 2022 | 755 | 0.500 |
Why?
|
| Lupus Erythematosus, Systemic | 12 | 2023 | 2159 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2018 | 10827 | 0.490 |
Why?
|
| Drug Administration Schedule | 18 | 2015 | 4899 | 0.490 |
Why?
|
| Pyrimidines | 12 | 2021 | 3016 | 0.480 |
Why?
|
| Efficiency | 1 | 2017 | 477 | 0.460 |
Why?
|
| Pituitary Gland | 1 | 2017 | 637 | 0.460 |
Why?
|
| Disease Progression | 25 | 2023 | 13502 | 0.460 |
Why?
|
| Immunocompromised Host | 5 | 2013 | 857 | 0.450 |
Why?
|
| Sulfonamides | 3 | 2019 | 1977 | 0.440 |
Why?
|
| Foot Joints | 1 | 2013 | 35 | 0.440 |
Why?
|
| Clinical Trials as Topic | 17 | 2019 | 8056 | 0.440 |
Why?
|
| Peptides, Cyclic | 8 | 2019 | 392 | 0.430 |
Why?
|
| Immunologic Factors | 7 | 2011 | 1588 | 0.410 |
Why?
|
| Glucocorticoids | 8 | 2021 | 2145 | 0.410 |
Why?
|
| Autoantibodies | 11 | 2017 | 2118 | 0.410 |
Why?
|
| Drug Resistance | 4 | 2015 | 1617 | 0.400 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3215 | 0.400 |
Why?
|
| Immunoglobulins | 4 | 2018 | 859 | 0.380 |
Why?
|
| Quality of Life | 13 | 2024 | 13308 | 0.380 |
Why?
|
| Injections, Subcutaneous | 8 | 2017 | 680 | 0.380 |
Why?
|
| Radiography | 20 | 2023 | 6965 | 0.380 |
Why?
|
| Opportunistic Infections | 4 | 2015 | 377 | 0.370 |
Why?
|
| Employment | 1 | 2017 | 1112 | 0.370 |
Why?
|
| Health Status | 15 | 2021 | 4081 | 0.370 |
Why?
|
| Prodrugs | 2 | 2011 | 259 | 0.360 |
Why?
|
| Isoxazoles | 3 | 2000 | 230 | 0.350 |
Why?
|
| Fibromyalgia | 3 | 2022 | 401 | 0.340 |
Why?
|
| Troponin T | 3 | 2024 | 774 | 0.340 |
Why?
|
| Health Resources | 1 | 2016 | 935 | 0.340 |
Why?
|
| Uric Acid | 4 | 2022 | 806 | 0.330 |
Why?
|
| Interleukin-17 | 4 | 2018 | 910 | 0.330 |
Why?
|
| Lung Diseases | 9 | 2019 | 1915 | 0.330 |
Why?
|
| Dermatomyositis | 2 | 2017 | 256 | 0.330 |
Why?
|
| Blood Sedimentation | 8 | 2017 | 234 | 0.320 |
Why?
|
| Gout Suppressants | 4 | 2022 | 177 | 0.320 |
Why?
|
| Fatigue | 7 | 2022 | 1544 | 0.320 |
Why?
|
| Disability Evaluation | 9 | 2016 | 1826 | 0.310 |
Why?
|
| Cyclosporins | 6 | 1991 | 216 | 0.300 |
Why?
|
| Polymyositis | 2 | 2006 | 75 | 0.300 |
Why?
|
| Joints | 10 | 2017 | 321 | 0.300 |
Why?
|
| Time Factors | 33 | 2021 | 40165 | 0.300 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2007 | 106 | 0.280 |
Why?
|
| Streptococcus pyogenes | 1 | 2009 | 294 | 0.270 |
Why?
|
| Cyclosporine | 3 | 1999 | 777 | 0.270 |
Why?
|
| Pyrroles | 3 | 2023 | 1137 | 0.270 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2021 | 279 | 0.270 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 319 | 0.260 |
Why?
|
| Prospective Studies | 36 | 2023 | 54303 | 0.250 |
Why?
|
| Pain Measurement | 7 | 2017 | 3528 | 0.250 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 58995 | 0.240 |
Why?
|
| Cohort Studies | 40 | 2022 | 41335 | 0.240 |
Why?
|
| Streptococcal Infections | 1 | 2009 | 617 | 0.240 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2005 | 173 | 0.240 |
Why?
|
| Single-Blind Method | 3 | 2024 | 1578 | 0.230 |
Why?
|
| Administration, Oral | 12 | 2018 | 4035 | 0.230 |
Why?
|
| Liver Cirrhosis | 5 | 2000 | 1931 | 0.230 |
Why?
|
| Arthrography | 3 | 2014 | 149 | 0.230 |
Why?
|
| Evidence-Based Medicine | 6 | 2013 | 3696 | 0.230 |
Why?
|
| Tripterygium | 1 | 2023 | 16 | 0.230 |
Why?
|
| Hospitals, University | 1 | 2005 | 568 | 0.220 |
Why?
|
| Pandemics | 3 | 2022 | 8624 | 0.220 |
Why?
|
| Sulfasalazine | 2 | 2004 | 84 | 0.220 |
Why?
|
| Prednisone | 12 | 2023 | 1565 | 0.220 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1864 | 0.220 |
Why?
|
| Auranofin | 3 | 1993 | 16 | 0.220 |
Why?
|
| Hydroxychloroquine | 6 | 2022 | 427 | 0.220 |
Why?
|
| Piperidines | 3 | 2021 | 1650 | 0.220 |
Why?
|
| Withholding Treatment | 3 | 2013 | 613 | 0.220 |
Why?
|
| Arthralgia | 3 | 2022 | 461 | 0.220 |
Why?
|
| Shock, Septic | 1 | 2009 | 761 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2023 | 10344 | 0.210 |
Why?
|
| Chikungunya virus | 1 | 2022 | 53 | 0.200 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2002 | 22 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 5643 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 3735 | 0.200 |
Why?
|
| Prognosis | 20 | 2021 | 29658 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 1039 | 0.200 |
Why?
|
| Leukotriene B4 | 3 | 1992 | 280 | 0.200 |
Why?
|
| Predictive Value of Tests | 12 | 2019 | 15289 | 0.190 |
Why?
|
| Inflammation Mediators | 4 | 2024 | 1881 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2019 | 15789 | 0.190 |
Why?
|
| Synovial Membrane | 5 | 2018 | 524 | 0.190 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 11903 | 0.190 |
Why?
|
| Inflammation | 6 | 2024 | 10756 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2803 | 0.180 |
Why?
|
| Treatment Failure | 5 | 2015 | 2648 | 0.180 |
Why?
|
| Adolescent | 35 | 2021 | 87810 | 0.180 |
Why?
|
| Collagenases | 2 | 2003 | 221 | 0.180 |
Why?
|
| Cholesterol, LDL | 3 | 2021 | 2420 | 0.180 |
Why?
|
| Purines | 3 | 2019 | 605 | 0.170 |
Why?
|
| Young Adult | 13 | 2021 | 58741 | 0.170 |
Why?
|
| Thrombocytopenia | 6 | 1994 | 1174 | 0.170 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39261 | 0.170 |
Why?
|
| Emphysema | 1 | 2022 | 240 | 0.170 |
Why?
|
| Georgia | 1 | 2019 | 190 | 0.170 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 255 | 0.170 |
Why?
|
| Polysaccharides | 3 | 2012 | 1016 | 0.170 |
Why?
|
| Research Design | 10 | 2019 | 6180 | 0.170 |
Why?
|
| Metalloendopeptidases | 2 | 2003 | 393 | 0.160 |
Why?
|
| Microcirculation | 1 | 2024 | 1278 | 0.160 |
Why?
|
| Kallikreins | 3 | 1989 | 231 | 0.160 |
Why?
|
| Pain | 8 | 2024 | 5066 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 5 | 2010 | 693 | 0.160 |
Why?
|
| Tuberculosis | 2 | 2009 | 2001 | 0.160 |
Why?
|
| Canada | 2 | 2022 | 2128 | 0.160 |
Why?
|
| Liver | 9 | 2000 | 7509 | 0.160 |
Why?
|
| Psychological Techniques | 1 | 2018 | 47 | 0.160 |
Why?
|
| Cardiovascular Diseases | 8 | 2024 | 15757 | 0.160 |
Why?
|
| Monosomy | 2 | 1995 | 52 | 0.160 |
Why?
|
| Myositis | 2 | 2008 | 269 | 0.160 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2018 | 34 | 0.160 |
Why?
|
| Risk Assessment | 10 | 2021 | 24123 | 0.160 |
Why?
|
| Pulmonary Embolism | 3 | 2021 | 2543 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 3 | 1992 | 359 | 0.150 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 1784 | 0.150 |
Why?
|
| Antigens, CD | 4 | 2019 | 4000 | 0.150 |
Why?
|
| Urate Oxidase | 3 | 2022 | 31 | 0.150 |
Why?
|
| Coronary Circulation | 1 | 2024 | 1577 | 0.150 |
Why?
|
| Pneumococcal Vaccines | 2 | 2013 | 397 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2021 | 1155 | 0.150 |
Why?
|
| Pharyngitis | 2 | 2016 | 220 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2016 | 17790 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1995 | 310 | 0.150 |
Why?
|
| Linear Models | 6 | 2019 | 5877 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2010 | 1796 | 0.140 |
Why?
|
| Prednisolone | 1 | 2018 | 327 | 0.140 |
Why?
|
| Lung | 7 | 2022 | 9994 | 0.140 |
Why?
|
| Logistic Models | 8 | 2020 | 13314 | 0.140 |
Why?
|
| Synovial Fluid | 5 | 2017 | 395 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2013 | 11712 | 0.140 |
Why?
|
| Pneumococcal Infections | 2 | 2013 | 503 | 0.140 |
Why?
|
| Consensus | 4 | 2023 | 3113 | 0.140 |
Why?
|
| Fenretinide | 1 | 1996 | 9 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2022 | 559 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 1075 | 0.140 |
Why?
|
| Deoxyglucose | 1 | 1997 | 333 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic | 2 | 1988 | 41 | 0.140 |
Why?
|
| Apyrase | 1 | 2019 | 373 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 502 | 0.140 |
Why?
|
| Immunoassay | 2 | 2011 | 746 | 0.130 |
Why?
|
| Motor Activity | 4 | 2015 | 2687 | 0.130 |
Why?
|
| Ancillary Services, Hospital | 1 | 1996 | 23 | 0.130 |
Why?
|
| Spondylitis, Ankylosing | 4 | 2019 | 152 | 0.130 |
Why?
|
| Risk Factors | 28 | 2022 | 74359 | 0.130 |
Why?
|
| Nasopharyngitis | 1 | 2015 | 10 | 0.130 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2018 | 306 | 0.130 |
Why?
|
| Data Mining | 3 | 2021 | 553 | 0.130 |
Why?
|
| Stomatitis, Aphthous | 1 | 1996 | 52 | 0.130 |
Why?
|
| Nurse's Role | 1 | 2017 | 188 | 0.130 |
Why?
|
| Familial Mediterranean Fever | 1 | 1996 | 65 | 0.130 |
Why?
|
| Patient Dropouts | 2 | 2013 | 412 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 1869 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1995 | 629 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2018 | 1827 | 0.130 |
Why?
|
| Tomography, Emission-Computed | 2 | 1997 | 1121 | 0.130 |
Why?
|
| Anemia, Aplastic | 3 | 1991 | 228 | 0.130 |
Why?
|
| Lymphadenitis | 1 | 1996 | 98 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2021 | 1717 | 0.120 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 115 | 0.120 |
Why?
|
| Autoimmune Diseases | 2 | 2022 | 2250 | 0.120 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 1994 | 28 | 0.120 |
Why?
|
| Age Factors | 11 | 2019 | 18416 | 0.120 |
Why?
|
| Lung Transplantation | 1 | 2024 | 1305 | 0.120 |
Why?
|
| Fees and Charges | 1 | 1996 | 191 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 274 | 0.120 |
Why?
|
| Fluorine Radioisotopes | 1 | 1997 | 413 | 0.120 |
Why?
|
| Delphi Technique | 3 | 2020 | 829 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 307 | 0.120 |
Why?
|
| Tachyphylaxis | 1 | 1994 | 54 | 0.120 |
Why?
|
| Models, Economic | 1 | 2018 | 719 | 0.120 |
Why?
|
| Antibodies, Neoplasm | 1 | 1995 | 280 | 0.120 |
Why?
|
| Biological Therapy | 1 | 2015 | 139 | 0.120 |
Why?
|
| Genome-Wide Association Study | 6 | 2019 | 12626 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2012 | 67 | 0.120 |
Why?
|
| Sjogren's Syndrome | 2 | 2014 | 235 | 0.120 |
Why?
|
| Boston | 5 | 2021 | 9280 | 0.110 |
Why?
|
| Forecasting | 3 | 2018 | 2932 | 0.110 |
Why?
|
| Longitudinal Studies | 9 | 2017 | 14495 | 0.110 |
Why?
|
| Low Back Pain | 1 | 2022 | 979 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 1996 | 324 | 0.110 |
Why?
|
| Misoprostol | 1 | 1994 | 93 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 1810 | 0.110 |
Why?
|
| Sex Factors | 6 | 2019 | 10547 | 0.110 |
Why?
|
| 14-3-3 Proteins | 1 | 2014 | 221 | 0.110 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2008 | 138 | 0.110 |
Why?
|
| Cost Control | 1 | 1996 | 630 | 0.110 |
Why?
|
| Biomedical Research | 3 | 2019 | 3426 | 0.110 |
Why?
|
| Interleukin-1 | 4 | 2010 | 1249 | 0.110 |
Why?
|
| Peer Group | 1 | 2018 | 674 | 0.110 |
Why?
|
| International Cooperation | 3 | 2015 | 1433 | 0.110 |
Why?
|
| Information Systems | 1 | 1995 | 398 | 0.110 |
Why?
|
| Pyrazoles | 3 | 2019 | 1999 | 0.110 |
Why?
|
| Neutropenia | 2 | 1995 | 884 | 0.110 |
Why?
|
| Chordoma | 1 | 1996 | 346 | 0.110 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 1299 | 0.100 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1992 | 93 | 0.100 |
Why?
|
| Bone Density | 3 | 2018 | 3534 | 0.100 |
Why?
|
| Antibodies | 5 | 2020 | 2421 | 0.100 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 25942 | 0.100 |
Why?
|
| Hypertension | 7 | 2014 | 8594 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.100 |
Why?
|
| Diarrhea | 2 | 2014 | 1319 | 0.100 |
Why?
|
| Vasculitis | 4 | 1990 | 523 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 877 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 2315 | 0.100 |
Why?
|
| Gilbert Disease | 1 | 2011 | 4 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2012 | 206 | 0.100 |
Why?
|
| Platelet Transfusion | 1 | 1994 | 294 | 0.100 |
Why?
|
| Databases as Topic | 2 | 2011 | 474 | 0.100 |
Why?
|
| Patient Selection | 4 | 2017 | 4283 | 0.100 |
Why?
|
| Gold Sodium Thiomalate | 3 | 1999 | 10 | 0.100 |
Why?
|
| Radius | 1 | 1994 | 440 | 0.100 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 12159 | 0.090 |
Why?
|
| Hydroxyurea | 1 | 1992 | 282 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 975 | 0.090 |
Why?
|
| Hyperbilirubinemia | 1 | 2011 | 74 | 0.090 |
Why?
|
| Muscular Diseases | 2 | 1989 | 551 | 0.090 |
Why?
|
| Leucovorin | 1 | 1993 | 641 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2021 | 5125 | 0.090 |
Why?
|
| Micrococcaceae | 1 | 1990 | 8 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 452 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 1399 | 0.090 |
Why?
|
| Galactose | 1 | 2012 | 297 | 0.090 |
Why?
|
| Antibodies, Heterophile | 1 | 2011 | 128 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 130 | 0.090 |
Why?
|
| Liver Failure | 1 | 1993 | 249 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2015 | 457 | 0.090 |
Why?
|
| Exercise | 2 | 2017 | 5787 | 0.090 |
Why?
|
| Bacterial Infections | 2 | 2007 | 1403 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2024 | 998 | 0.090 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2010 | 30 | 0.090 |
Why?
|
| Infectious Mononucleosis | 1 | 1991 | 133 | 0.090 |
Why?
|
| Professional Practice | 1 | 2012 | 313 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2018 | 1057 | 0.090 |
Why?
|
| B-Lymphocytes | 3 | 2017 | 4742 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 667 | 0.090 |
Why?
|
| Incidence | 9 | 2021 | 21392 | 0.090 |
Why?
|
| Liver Diseases | 5 | 1996 | 1302 | 0.090 |
Why?
|
| Societies, Medical | 4 | 2021 | 3905 | 0.090 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1990 | 58 | 0.090 |
Why?
|
| Self Report | 3 | 2017 | 3711 | 0.090 |
Why?
|
| Algorithms | 5 | 2013 | 13981 | 0.090 |
Why?
|
| Herpes Zoster | 2 | 2016 | 251 | 0.090 |
Why?
|
| Neutrophils | 4 | 2002 | 3767 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 1990 | 115 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 664 | 0.080 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 224 | 0.080 |
Why?
|
| Nucleotide Deaminases | 1 | 2009 | 11 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1378 | 0.080 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2009 | 18 | 0.080 |
Why?
|
| Bilirubin | 1 | 2011 | 438 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1989 | 2197 | 0.080 |
Why?
|
| HLA-DR Antigens | 4 | 2018 | 630 | 0.080 |
Why?
|
| Pregnadienes | 1 | 1988 | 24 | 0.080 |
Why?
|
| Eicosanoids | 1 | 1991 | 278 | 0.080 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 1809 | 0.080 |
Why?
|
| Adiposity | 1 | 2019 | 1858 | 0.080 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 1989 | 83 | 0.080 |
Why?
|
| Metacarpal Bones | 1 | 2009 | 75 | 0.080 |
Why?
|
| Danazol | 1 | 1988 | 45 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 1994 | 911 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2852 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 5 | 2023 | 7475 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2010 | 318 | 0.080 |
Why?
|
| Polyradiculoneuropathy | 1 | 1988 | 65 | 0.080 |
Why?
|
| Blood Cell Count | 1 | 1989 | 397 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2017 | 6238 | 0.080 |
Why?
|
| Neuroblastoma | 3 | 1988 | 1252 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2014 | 2688 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2010 | 513 | 0.080 |
Why?
|
| Aortitis | 1 | 1989 | 74 | 0.080 |
Why?
|
| Cell-Derived Microparticles | 1 | 2010 | 161 | 0.080 |
Why?
|
| Myocardium | 1 | 2021 | 4700 | 0.080 |
Why?
|
| Interleukin-1alpha | 1 | 2008 | 86 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2021 | 2809 | 0.080 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 12531 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 687 | 0.070 |
Why?
|
| Fatal Outcome | 4 | 2009 | 1832 | 0.070 |
Why?
|
| HLA-DR4 Antigen | 1 | 2007 | 29 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4024 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 238 | 0.070 |
Why?
|
| Medicare | 5 | 2022 | 6786 | 0.070 |
Why?
|
| Acyltransferases | 1 | 1989 | 305 | 0.070 |
Why?
|
| Blood | 1 | 1989 | 586 | 0.070 |
Why?
|
| Glucosamine | 1 | 1987 | 128 | 0.070 |
Why?
|
| Collagen | 3 | 2018 | 2636 | 0.070 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 608 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 643 | 0.070 |
Why?
|
| Placebos | 2 | 2006 | 1668 | 0.070 |
Why?
|
| Prenatal Diagnosis | 1 | 1994 | 1264 | 0.070 |
Why?
|
| Infarction | 1 | 1988 | 248 | 0.070 |
Why?
|
| Database Management Systems | 1 | 2008 | 258 | 0.070 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 20080 | 0.070 |
Why?
|
| Apolipoprotein A-I | 2 | 2021 | 297 | 0.070 |
Why?
|
| Case-Control Studies | 11 | 2020 | 22053 | 0.070 |
Why?
|
| North America | 1 | 2010 | 1284 | 0.070 |
Why?
|
| Leukopenia | 1 | 1987 | 211 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2012 | 1091 | 0.070 |
Why?
|
| Medical Records | 3 | 2007 | 1407 | 0.070 |
Why?
|
| Apolipoproteins B | 2 | 2021 | 388 | 0.070 |
Why?
|
| Polycythemia | 1 | 1987 | 125 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4353 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1991 | 241 | 0.070 |
Why?
|
| Glomerulonephritis | 1 | 1988 | 337 | 0.070 |
Why?
|
| Serum | 1 | 2007 | 211 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2007 | 373 | 0.070 |
Why?
|
| T-Lymphocytes | 5 | 2012 | 10181 | 0.070 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 442 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 6544 | 0.070 |
Why?
|
| Diclofenac | 1 | 2006 | 67 | 0.070 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1987 | 106 | 0.070 |
Why?
|
| Kidney | 5 | 1994 | 7064 | 0.070 |
Why?
|
| Candidiasis | 2 | 2006 | 363 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 2 | 1999 | 416 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1991 | 494 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2018 | 2913 | 0.070 |
Why?
|
| ROC Curve | 4 | 2015 | 3568 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2020 | 788 | 0.070 |
Why?
|
| Office Visits | 1 | 2010 | 597 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 393 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 298 | 0.060 |
Why?
|
| Drug Interactions | 4 | 2012 | 1428 | 0.060 |
Why?
|
| Sacrococcygeal Region | 1 | 1985 | 53 | 0.060 |
Why?
|
| Cross-Over Studies | 3 | 2015 | 2061 | 0.060 |
Why?
|
| Comorbidity | 4 | 2015 | 10551 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2942 | 0.060 |
Why?
|
| Child, Preschool | 23 | 2009 | 42063 | 0.060 |
Why?
|
| Bone Marrow | 6 | 1990 | 2912 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2008 | 597 | 0.060 |
Why?
|
| Alleles | 5 | 2013 | 6898 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2009 | 419 | 0.060 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 11891 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2283 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2009 | 666 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2017 | 3185 | 0.060 |
Why?
|
| Azathioprine | 2 | 2006 | 356 | 0.060 |
Why?
|
| Neoplasms | 9 | 2010 | 22072 | 0.060 |
Why?
|
| Haplotypes | 2 | 2008 | 2764 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 1992 | 1420 | 0.060 |
Why?
|
| Teratoma | 2 | 1985 | 403 | 0.060 |
Why?
|
| United States | 13 | 2022 | 72461 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2013 | 1182 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 14660 | 0.060 |
Why?
|
| Paraplegia | 1 | 1985 | 162 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2009 | 1218 | 0.060 |
Why?
|
| RNA | 1 | 2015 | 2722 | 0.060 |
Why?
|
| Quality of Health Care | 4 | 2014 | 4360 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 1996 | 2781 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 3804 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 321 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 8035 | 0.060 |
Why?
|
| Antigens, CD19 | 2 | 2006 | 424 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2019 | 6360 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1986 | 130 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2018 | 4122 | 0.060 |
Why?
|
| Mass Screening | 2 | 2012 | 5423 | 0.060 |
Why?
|
| Chronic Disease | 8 | 2017 | 9287 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 1995 | 3602 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 1469 | 0.060 |
Why?
|
| Biopsy | 8 | 2000 | 6771 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 4013 | 0.060 |
Why?
|
| Receptors, Chemokine | 2 | 2017 | 655 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2009 | 3157 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2023 | 1521 | 0.060 |
Why?
|
| Hemangioendothelioma | 1 | 1984 | 111 | 0.060 |
Why?
|
| Congresses as Topic | 2 | 2019 | 805 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2009 | 6551 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2005 | 641 | 0.060 |
Why?
|
| Psoriasis | 4 | 2003 | 940 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 1544 | 0.060 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1984 | 187 | 0.060 |
Why?
|
| Creatine Kinase | 1 | 2006 | 691 | 0.060 |
Why?
|
| Sulfones | 1 | 2006 | 447 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 1204 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 738 | 0.060 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 631 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2006 | 1722 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 1997 | 4878 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2017 | 2981 | 0.060 |
Why?
|
| Respiratory Function Tests | 3 | 2019 | 1683 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 1989 | 1440 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2015 | 1636 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1403 | 0.060 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2003 | 50 | 0.060 |
Why?
|
| Skin | 1 | 2017 | 4466 | 0.050 |
Why?
|
| Melanoma | 1 | 2022 | 5697 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2010 | 12766 | 0.050 |
Why?
|
| Range of Motion, Articular | 2 | 2007 | 1583 | 0.050 |
Why?
|
| Pulmonary Fibrosis | 2 | 1992 | 506 | 0.050 |
Why?
|
| Ganglioneuroma | 1 | 1983 | 53 | 0.050 |
Why?
|
| Hypotension | 1 | 2009 | 883 | 0.050 |
Why?
|
| Pennsylvania | 3 | 2011 | 615 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2006 | 478 | 0.050 |
Why?
|
| Muscle Weakness | 1 | 2006 | 413 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 2 | 1996 | 2882 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1933 | 0.050 |
Why?
|
| Crohn Disease | 3 | 2009 | 2275 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2014 | 2165 | 0.050 |
Why?
|
| Enzyme Precursors | 1 | 2003 | 174 | 0.050 |
Why?
|
| Retrospective Studies | 11 | 2024 | 80372 | 0.050 |
Why?
|
| Dysgerminoma | 1 | 1982 | 66 | 0.050 |
Why?
|
| Antibody Formation | 2 | 2023 | 1400 | 0.050 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2003 | 142 | 0.050 |
Why?
|
| Sarcoma | 2 | 1991 | 1786 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 1983 | 310 | 0.050 |
Why?
|
| Finger Joint | 1 | 2023 | 108 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1829 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5799 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1991 | 1152 | 0.050 |
Why?
|
| Hypothyroidism | 1 | 1987 | 665 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2773 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2005 | 430 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 2421 | 0.050 |
Why?
|
| Principal Component Analysis | 2 | 2021 | 940 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2014 | 2932 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2003 | 0.050 |
Why?
|
| Leukemia | 1 | 1990 | 1520 | 0.050 |
Why?
|
| Dianhydrogalactitol | 1 | 1981 | 3 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1297 | 0.050 |
Why?
|
| Monocytes | 5 | 1992 | 2575 | 0.050 |
Why?
|
| Sugar Alcohols | 1 | 1981 | 17 | 0.050 |
Why?
|
| Needs Assessment | 2 | 2019 | 1139 | 0.050 |
Why?
|
| Liver Function Tests | 2 | 1994 | 524 | 0.050 |
Why?
|
| Brain Neoplasms | 5 | 1997 | 8986 | 0.050 |
Why?
|
| Pregnancy | 4 | 2019 | 29749 | 0.050 |
Why?
|
| Caffeine | 1 | 2006 | 702 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 1983 | 286 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2023 | 295 | 0.050 |
Why?
|
| Synovitis | 1 | 1983 | 215 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2024 | 965 | 0.050 |
Why?
|
| Chemokines | 3 | 2015 | 962 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 4 | 1994 | 1190 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1984 | 329 | 0.050 |
Why?
|
| Wrist Joint | 1 | 2023 | 265 | 0.050 |
Why?
|
| Diet | 2 | 2017 | 8010 | 0.050 |
Why?
|
| Splenectomy | 1 | 1982 | 391 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 315 | 0.050 |
Why?
|
| Osteoarthritis | 2 | 2006 | 1055 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 1996 | 13630 | 0.050 |
Why?
|
| Child | 21 | 1997 | 79806 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 649 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 1982 | 1975 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2003 | 8552 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2010 | 2618 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2024 | 20509 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2003 | 8555 | 0.050 |
Why?
|
| Cisplatin | 1 | 1987 | 1644 | 0.050 |
Why?
|
| Infant | 15 | 1995 | 36060 | 0.040 |
Why?
|
| Genotype | 6 | 2011 | 12960 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 1231 | 0.040 |
Why?
|
| Densitometry | 1 | 1980 | 151 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 3143 | 0.040 |
Why?
|
| Physician's Role | 1 | 2007 | 918 | 0.040 |
Why?
|
| Diagnosis, Differential | 5 | 2009 | 12965 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3726 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2004 | 486 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2023 | 496 | 0.040 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2024 | 329 | 0.040 |
Why?
|
| Mycoplasma Infections | 1 | 1980 | 120 | 0.040 |
Why?
|
| Asthma | 2 | 2009 | 6172 | 0.040 |
Why?
|
| Syndrome | 3 | 1996 | 3280 | 0.040 |
Why?
|
| Penicillamine | 1 | 1999 | 60 | 0.040 |
Why?
|
| False Positive Reactions | 3 | 1997 | 956 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 1992 | 663 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 1987 | 1030 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2005 | 1195 | 0.040 |
Why?
|
| Brazil | 1 | 2023 | 1218 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5785 | 0.040 |
Why?
|
| Cholesterol | 2 | 2021 | 2924 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 346 | 0.040 |
Why?
|
| Hematologic Diseases | 3 | 1989 | 496 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2010 | 2520 | 0.040 |
Why?
|
| Life Style | 3 | 2020 | 3896 | 0.040 |
Why?
|
| Kidney Diseases | 4 | 1994 | 2093 | 0.040 |
Why?
|
| Family Health | 2 | 1996 | 1257 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 2557 | 0.040 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2024 | 571 | 0.040 |
Why?
|
| Reference Values | 3 | 2014 | 4925 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 1385 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 5075 | 0.040 |
Why?
|
| Cytokines | 2 | 2011 | 7343 | 0.040 |
Why?
|
| Proteomics | 2 | 2022 | 3817 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 1984 | 708 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 6538 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 587 | 0.040 |
Why?
|
| Morbidity | 2 | 2015 | 1765 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 1174 | 0.040 |
Why?
|
| Telomere | 1 | 2024 | 933 | 0.040 |
Why?
|
| Random Allocation | 3 | 1988 | 2394 | 0.040 |
Why?
|
| Macrophage-Activating Factors | 1 | 2017 | 21 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2013 | 3836 | 0.040 |
Why?
|
| Phenotype | 6 | 2021 | 16546 | 0.040 |
Why?
|
| Prevalence | 4 | 2020 | 15687 | 0.040 |
Why?
|
| Risk | 6 | 2008 | 9631 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 566 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2017 | 59 | 0.040 |
Why?
|
| Interleukin-23 | 1 | 2018 | 197 | 0.030 |
Why?
|
| Receptors, CXCR5 | 1 | 2017 | 88 | 0.030 |
Why?
|
| Gold | 3 | 1990 | 484 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 2007 | 0.030 |
Why?
|
| Immunologic Memory | 3 | 2018 | 1354 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2016 | 107 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 1999 | 606 | 0.030 |
Why?
|
| Cysts | 1 | 1982 | 683 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 191 | 0.030 |
Why?
|
| Sepsis | 1 | 2010 | 2592 | 0.030 |
Why?
|
| Cecal Diseases | 1 | 1996 | 49 | 0.030 |
Why?
|
| Encephalitis | 1 | 1980 | 437 | 0.030 |
Why?
|
| Chemokines, CXC | 1 | 1998 | 421 | 0.030 |
Why?
|
| Recurrence | 3 | 2013 | 8482 | 0.030 |
Why?
|
| Nausea | 1 | 1999 | 678 | 0.030 |
Why?
|
| Doxorubicin | 3 | 1996 | 2209 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 2417 | 0.030 |
Why?
|
| Colitis | 1 | 1984 | 1229 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4775 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2018 | 361 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2017 | 250 | 0.030 |
Why?
|
| Ifosfamide | 1 | 1996 | 232 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 1998 | 488 | 0.030 |
Why?
|
| Aurothioglucose | 1 | 1995 | 11 | 0.030 |
Why?
|
| Models, Biological | 1 | 2012 | 9467 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 3 | 1993 | 2693 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2015 | 48 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2017 | 9716 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2002 | 5889 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1995 | 365 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 600 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2015 | 60 | 0.030 |
Why?
|
| Karyotyping | 2 | 1995 | 1171 | 0.030 |
Why?
|
| Postmenopause | 2 | 2018 | 2509 | 0.030 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 5325 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 71 | 0.030 |
Why?
|
| Cordocentesis | 1 | 1994 | 10 | 0.030 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1997 | 243 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 1996 | 176 | 0.030 |
Why?
|
| Ulcer | 1 | 1996 | 204 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 1351 | 0.030 |
Why?
|
| Research | 2 | 2019 | 1974 | 0.030 |
Why?
|
| Allopurinol | 1 | 1996 | 198 | 0.030 |
Why?
|
| Cartilage | 1 | 2018 | 806 | 0.030 |
Why?
|
| Carcinoma, Endometrioid | 1 | 1997 | 276 | 0.030 |
Why?
|
| Down Syndrome | 2 | 1989 | 892 | 0.030 |
Why?
|
| Infant, Newborn | 10 | 1990 | 26181 | 0.030 |
Why?
|
| HLA-DR3 Antigen | 1 | 2014 | 33 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2018 | 1600 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 1995 | 289 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 1996 | 250 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 1992 | 128 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2698 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2007 | 3598 | 0.030 |
Why?
|
| Salicylates | 2 | 1986 | 127 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1995 | 369 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 422 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1928 | 0.030 |
Why?
|
| Hemolysis | 1 | 1996 | 423 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 1031 | 0.030 |
Why?
|
| Software | 1 | 2007 | 4419 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1989 | 4215 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2017 | 1161 | 0.030 |
Why?
|
| Health Surveys | 2 | 2017 | 4063 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 1993 | 47 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 1032 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 6465 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1523 | 0.030 |
Why?
|
| Health Priorities | 1 | 2016 | 374 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 1343 | 0.030 |
Why?
|
| Triglycerides | 1 | 2021 | 2476 | 0.030 |
Why?
|
| Glycoproteins | 2 | 1995 | 2208 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2000 | 817 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 875 | 0.030 |
Why?
|
| Platelet Activating Factor | 2 | 1990 | 143 | 0.030 |
Why?
|
| Thalidomide | 1 | 2018 | 884 | 0.030 |
Why?
|
| Genes, ras | 1 | 1995 | 655 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2006 | 298 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 1994 | 109 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 983 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2013 | 177 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1993 | 1547 | 0.030 |
Why?
|
| Hip Joint | 2 | 2009 | 1006 | 0.030 |
Why?
|
| Liver Neoplasms | 3 | 1985 | 4319 | 0.030 |
Why?
|
| Massachusetts | 1 | 2005 | 8803 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 1994 | 139 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2024 | 3112 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 252 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1999 | 2362 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 1994 | 174 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1987 | 3218 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 340 | 0.030 |
Why?
|
| Health Behavior | 2 | 2014 | 2622 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 468 | 0.030 |
Why?
|
| Iris | 1 | 1993 | 231 | 0.030 |
Why?
|
| Interleukins | 1 | 2017 | 785 | 0.020 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 7806 | 0.020 |
Why?
|
| Iron | 2 | 1994 | 1786 | 0.020 |
Why?
|
| Aging | 1 | 1991 | 8651 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1994 | 732 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2014 | 495 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1990 | 9276 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 147 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 2001 | 0.020 |
Why?
|
| Leptin | 1 | 2019 | 1591 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1987 | 4312 | 0.020 |
Why?
|
| Perception | 1 | 2017 | 1195 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 2101 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 3986 | 0.020 |
Why?
|
| Calcimycin | 1 | 1990 | 213 | 0.020 |
Why?
|
| SOXD Transcription Factors | 1 | 2010 | 44 | 0.020 |
Why?
|
| Phospholipases | 1 | 1990 | 76 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1991 | 291 | 0.020 |
Why?
|
| Vaccination | 1 | 2023 | 3361 | 0.020 |
Why?
|
| Pancytopenia | 2 | 1981 | 101 | 0.020 |
Why?
|
| Receptors, Collagen | 1 | 2010 | 25 | 0.020 |
Why?
|
| Genomics | 1 | 2006 | 5794 | 0.020 |
Why?
|
| Dexamethasone | 2 | 1996 | 1927 | 0.020 |
Why?
|
| Headache | 2 | 2016 | 1249 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 716 | 0.020 |
Why?
|
| Hospitalization | 2 | 2008 | 10790 | 0.020 |
Why?
|
| Genome, Human | 3 | 2008 | 4417 | 0.020 |
Why?
|
| Steroids | 1 | 2015 | 928 | 0.020 |
Why?
|
| Lymphocyte Activation | 3 | 2012 | 5496 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1817 | 0.020 |
Why?
|
| Extracellular Matrix | 2 | 2010 | 1726 | 0.020 |
Why?
|
| Creatinine | 3 | 1991 | 1903 | 0.020 |
Why?
|
| Life Tables | 1 | 1990 | 365 | 0.020 |
Why?
|
| Heart Failure | 2 | 2019 | 11847 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1990 | 294 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1982 | 2299 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2514 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2018 | 2493 | 0.020 |
Why?
|
| Animals | 7 | 2024 | 167963 | 0.020 |
Why?
|
| Thyroid Hormones | 2 | 1995 | 403 | 0.020 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 1990 | 224 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 1155 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 1989 | 15 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 877 | 0.020 |
Why?
|
| Growth Substances | 1 | 1992 | 768 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 36290 | 0.020 |
Why?
|
| Research Personnel | 1 | 2014 | 582 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 801 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 1994 | 704 | 0.020 |
Why?
|
| Kinins | 1 | 1989 | 14 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1056 | 0.020 |
Why?
|
| Probenecid | 1 | 1989 | 73 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 630 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2010 | 285 | 0.020 |
Why?
|
| Child Abuse | 1 | 1998 | 1067 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 9411 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 718 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 1998 | 4555 | 0.020 |
Why?
|
| Mycobacterium kansasii | 1 | 2008 | 8 | 0.020 |
Why?
|
| Mycobacterium avium | 1 | 2008 | 28 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 987 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1990 | 433 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 628 | 0.020 |
Why?
|
| Antacids | 1 | 1989 | 94 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 1995 | 965 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 1989 | 107 | 0.020 |
Why?
|
| Cyclophosphamide | 4 | 1993 | 2221 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2012 | 1991 | 0.020 |
Why?
|
| Nervous System Malformations | 1 | 1990 | 244 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 1724 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 315 | 0.020 |
Why?
|
| Mortality | 1 | 2020 | 2916 | 0.020 |
Why?
|
| Self Care | 1 | 2013 | 793 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 2 | 2009 | 928 | 0.020 |
Why?
|
| Phenytoin | 1 | 1989 | 188 | 0.020 |
Why?
|
| Dermatology | 1 | 2018 | 914 | 0.020 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1988 | 27 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1994 | 1677 | 0.020 |
Why?
|
| Churg-Strauss Syndrome | 1 | 1988 | 74 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 1990 | 342 | 0.020 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 1987 | 19 | 0.020 |
Why?
|
| Giant Cell Arteritis | 2 | 1982 | 295 | 0.020 |
Why?
|
| Drug Industry | 1 | 2014 | 789 | 0.020 |
Why?
|
| Aorta | 2 | 2013 | 2039 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5201 | 0.020 |
Why?
|
| Ribose | 1 | 1987 | 63 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 2007 | 132 | 0.020 |
Why?
|
| Histamine H2 Antagonists | 1 | 1989 | 167 | 0.020 |
Why?
|
| Tablets | 1 | 1988 | 149 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 2819 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 2628 | 0.020 |
Why?
|
| Hydrops Fetalis | 1 | 1988 | 109 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2754 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 1697 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 861 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 635 | 0.020 |
Why?
|
| Family | 1 | 1998 | 3189 | 0.020 |
Why?
|
| Smoking | 1 | 2024 | 9073 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 1998 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 1431 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2007 | 149 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 29932 | 0.020 |
Why?
|
| Erythropoiesis | 1 | 1990 | 682 | 0.020 |
Why?
|
| Hand | 2 | 2009 | 903 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1788 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1994 | 1745 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 6216 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2010 | 660 | 0.020 |
Why?
|
| Food, Fortified | 1 | 1987 | 189 | 0.020 |
Why?
|
| Vincristine | 2 | 1993 | 1039 | 0.020 |
Why?
|
| Coccyx | 1 | 1985 | 13 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1989 | 625 | 0.020 |
Why?
|
| Half-Life | 2 | 2003 | 652 | 0.020 |
Why?
|
| British Columbia | 1 | 2006 | 240 | 0.020 |
Why?
|
| Cerebral Arterial Diseases | 1 | 1986 | 82 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2828 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1535 | 0.020 |
Why?
|
| Fasciitis | 1 | 1986 | 67 | 0.020 |
Why?
|
| Lithium | 1 | 1989 | 596 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 685 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 2515 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1995 | 1394 | 0.020 |
Why?
|
| Babesiosis | 1 | 1986 | 92 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2012 | 2415 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5508 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1628 | 0.020 |
Why?
|
| Stroke | 3 | 2019 | 9962 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 717 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2006 | 204 | 0.020 |
Why?
|
| Leukocytes | 2 | 1998 | 2026 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2015 | 2985 | 0.020 |
Why?
|
| Mothers | 1 | 1996 | 2186 | 0.020 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1986 | 155 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 1987 | 365 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2009 | 697 | 0.020 |
Why?
|
| Thrombosis | 1 | 2019 | 3052 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1987 | 232 | 0.020 |
Why?
|
| Pharmacoepidemiology | 1 | 2008 | 350 | 0.020 |
Why?
|
| HLA Antigens | 2 | 1988 | 1368 | 0.020 |
Why?
|
| Cell Movement | 1 | 2017 | 5206 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1988 | 335 | 0.010 |
Why?
|
| Laminectomy | 1 | 1985 | 224 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 1987 | 266 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2012 | 5039 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 911 | 0.010 |
Why?
|
| Technetium | 2 | 1983 | 321 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 5397 | 0.010 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1984 | 91 | 0.010 |
Why?
|
| False Negative Reactions | 2 | 1983 | 573 | 0.010 |
Why?
|
| Muscles | 1 | 1989 | 1581 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 6659 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1987 | 349 | 0.010 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2003 | 33 | 0.010 |
Why?
|
| Electromyography | 1 | 1989 | 1388 | 0.010 |
Why?
|
| Fish Oils | 1 | 1987 | 482 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1824 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 1266 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2014 | 3442 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 1736 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2008 | 919 | 0.010 |
Why?
|
| Japan | 1 | 1988 | 1369 | 0.010 |
Why?
|
| Thigh | 1 | 1984 | 240 | 0.010 |
Why?
|
| Age of Onset | 1 | 2010 | 3301 | 0.010 |
Why?
|
| Europe | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Colon | 2 | 1997 | 1788 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1985 | 1446 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1983 | 129 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2008 | 2381 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1990 | 21025 | 0.010 |
Why?
|
| Mental Health | 1 | 2017 | 3213 | 0.010 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1985 | 338 | 0.010 |
Why?
|
| Endothelium | 1 | 1985 | 764 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10446 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2012 | 2566 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 4625 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1989 | 1097 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 3465 | 0.010 |
Why?
|
| Infertility, Male | 1 | 1985 | 396 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 1991 | 2180 | 0.010 |
Why?
|
| Outpatients | 1 | 2010 | 1607 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1982 | 304 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1985 | 916 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1988 | 1207 | 0.010 |
Why?
|
| Spine | 1 | 2009 | 1111 | 0.010 |
Why?
|
| Ependymoma | 2 | 1983 | 320 | 0.010 |
Why?
|
| Polymyalgia Rheumatica | 1 | 1982 | 53 | 0.010 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1982 | 44 | 0.010 |
Why?
|
| Rheumatic Fever | 1 | 1982 | 75 | 0.010 |
Why?
|
| Blood Donors | 1 | 1984 | 343 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1982 | 206 | 0.010 |
Why?
|
| Bursitis | 1 | 1982 | 80 | 0.010 |
Why?
|
| Cryoglobulinemia | 1 | 1982 | 84 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2717 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2008 | 1889 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 1997 | 6315 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1990 | 2299 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2019 | 12914 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1996 | 3455 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1500 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1981 | 63 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2295 | 0.010 |
Why?
|
| Latex Fixation Tests | 1 | 1980 | 29 | 0.010 |
Why?
|
| Observer Variation | 1 | 2007 | 2601 | 0.010 |
Why?
|
| Epitopes | 1 | 2007 | 2503 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 1981 | 95 | 0.010 |
Why?
|
| Mycoplasma pneumoniae | 1 | 1980 | 43 | 0.010 |
Why?
|
| Sulfur | 1 | 1981 | 163 | 0.010 |
Why?
|
| Age Distribution | 1 | 2006 | 2893 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 1868 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7588 | 0.010 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1982 | 227 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1981 | 195 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2006 | 2608 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2006 | 1191 | 0.010 |
Why?
|
| Infertility, Female | 1 | 1985 | 759 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1982 | 560 | 0.010 |
Why?
|
| Myofibrils | 1 | 2000 | 141 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2010 | 4090 | 0.010 |
Why?
|
| Urogenital Neoplasms | 1 | 1981 | 135 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2017 | 11481 | 0.010 |
Why?
|
| Choroid Plexus | 1 | 1982 | 237 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1989 | 2061 | 0.010 |
Why?
|
| Arthritis, Infectious | 1 | 1982 | 345 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1982 | 544 | 0.010 |
Why?
|
| Autoantigens | 1 | 2003 | 877 | 0.010 |
Why?
|
| Protein Binding | 1 | 2011 | 9335 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2234 | 0.010 |
Why?
|
| Abdomen | 1 | 1984 | 1130 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 1980 | 488 | 0.010 |
Why?
|
| Pneumothorax | 1 | 1982 | 379 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1990 | 3600 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23376 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1982 | 344 | 0.010 |
Why?
|
| Arm | 1 | 1981 | 583 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 3707 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1997 | 6853 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1982 | 1631 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 2003 | 520 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1982 | 13262 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9530 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1148 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 1871 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2009 | 3811 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1985 | 1089 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2009 | 2041 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 1998 | 238 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1989 | 10182 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 1998 | 316 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2010 | 18957 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1995 | 7408 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1986 | 1801 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1984 | 3618 | 0.010 |
Why?
|
| Lipids | 1 | 1987 | 3336 | 0.010 |
Why?
|
| Knee Joint | 2 | 1982 | 1663 | 0.010 |
Why?
|
| Lasers | 1 | 1980 | 952 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 1989 | 3150 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 330 | 0.010 |
Why?
|
| Mice | 3 | 2010 | 81208 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 2695 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16939 | 0.010 |
Why?
|
| Femur | 1 | 1981 | 1302 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1998 | 598 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 1998 | 810 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 14372 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1981 | 1328 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1995 | 317 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1995 | 201 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1994 | 123 | 0.010 |
Why?
|
| Thioguanine | 1 | 1993 | 44 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1995 | 302 | 0.010 |
Why?
|
| Haemophilus influenzae | 1 | 1994 | 180 | 0.010 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1995 | 241 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1986 | 2471 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1993 | 156 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1989 | 4897 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1993 | 211 | 0.010 |
Why?
|
| Zymosan | 1 | 1992 | 136 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1995 | 280 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1993 | 433 | 0.010 |
Why?
|
| Clone Cells | 1 | 1995 | 1660 | 0.010 |
Why?
|
| Knee Prosthesis | 1 | 1995 | 394 | 0.010 |
Why?
|
| Asparaginase | 1 | 1993 | 240 | 0.010 |
Why?
|
| Etoposide | 1 | 1993 | 630 | 0.010 |
Why?
|
| Sputum | 1 | 1994 | 503 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 22023 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 696 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 778 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1990 | 53 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1990 | 84 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 18137 | 0.010 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1990 | 45 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 1993 | 391 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 351 | 0.010 |
Why?
|
| Glioma | 2 | 1983 | 3420 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 6131 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1998 | 2611 | 0.010 |
Why?
|
| Acute Disease | 2 | 1996 | 7269 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 4578 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1989 | 155 | 0.010 |
Why?
|
| Colonoscopy | 1 | 1997 | 1387 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 187 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1981 | 2532 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1993 | 1818 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1997 | 2608 | 0.000 |
Why?
|
| Partial Thromboplastin Time | 1 | 1987 | 205 | 0.000 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 1986 | 58 | 0.000 |
Why?
|
| Salvage Therapy | 1 | 1993 | 1268 | 0.000 |
Why?
|
| Blood Coagulation Tests | 1 | 1987 | 270 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 6068 | 0.000 |
Why?
|
| Salicylic Acid | 1 | 1986 | 64 | 0.000 |
Why?
|
| Social Support | 1 | 1996 | 2145 | 0.000 |
Why?
|
| Staphylococcus aureus | 1 | 1994 | 1462 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1986 | 361 | 0.000 |
Why?
|
| Thromboplastin | 1 | 1987 | 286 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1996 | 6015 | 0.000 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1986 | 102 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1990 | 2116 | 0.000 |
Why?
|
| Plasminogen Activators | 1 | 1985 | 199 | 0.000 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1986 | 133 | 0.000 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4925 | 0.000 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 1984 | 77 | 0.000 |
Why?
|
| Hematocrit | 1 | 1986 | 629 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1985 | 818 | 0.000 |
Why?
|
| Spleen | 1 | 1990 | 2298 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1985 | 2094 | 0.000 |
Why?
|
| Haploidy | 1 | 1984 | 133 | 0.000 |
Why?
|
| New York | 1 | 1986 | 875 | 0.000 |
Why?
|
| Elastin | 1 | 1985 | 301 | 0.000 |
Why?
|
| Cerebral Arteries | 1 | 1986 | 493 | 0.000 |
Why?
|
| Leukemia, Myeloid | 1 | 1986 | 695 | 0.000 |
Why?
|
| Lymphatic System | 1 | 1985 | 254 | 0.000 |
Why?
|
| Sugar Acids | 1 | 1983 | 23 | 0.000 |
Why?
|
| Diatrizoate Meglumine | 1 | 1983 | 79 | 0.000 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1983 | 67 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1990 | 1415 | 0.000 |
Why?
|
| Pentetic Acid | 1 | 1983 | 209 | 0.000 |
Why?
|
| HLA-B Antigens | 1 | 1984 | 331 | 0.000 |
Why?
|
| Bursa, Synovial | 1 | 1982 | 25 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 2000 | 5130 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12446 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13451 | 0.000 |
Why?
|
| Retinal Artery | 1 | 1982 | 109 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 11071 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1984 | 782 | 0.000 |
Why?
|
| Arthrodesis | 1 | 1982 | 186 | 0.000 |
Why?
|
| Temporal Arteries | 1 | 1982 | 148 | 0.000 |
Why?
|
| Cerebral Angiography | 1 | 1986 | 1274 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 17624 | 0.000 |
Why?
|
| Anemia | 1 | 1989 | 1511 | 0.000 |
Why?
|
| Cattle | 1 | 1985 | 3847 | 0.000 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1985 | 1485 | 0.000 |
Why?
|
| Astrocytoma | 1 | 1983 | 775 | 0.000 |
Why?
|
| Kinetics | 1 | 1986 | 6377 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1985 | 1504 | 0.000 |
Why?
|
| Cell Division | 1 | 1985 | 4463 | 0.000 |
Why?
|
| Medulloblastoma | 1 | 1983 | 679 | 0.000 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1982 | 752 | 0.000 |
Why?
|
| Gene Frequency | 1 | 1984 | 3615 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1986 | 1647 | 0.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1982 | 1375 | 0.000 |
Why?
|
| Brain | 1 | 1982 | 26951 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1988 | 8525 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1986 | 6189 | 0.000 |
Why?
|
| Rats | 1 | 1985 | 23711 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1986 | 5351 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1986 | 6796 | 0.000 |
Why?
|